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The use of medicines during pregnancy is poorly described in African 
settings. With the introduction of novel therapies and the expansion 
of mass treatment campaigns for widely prevalent diseases such as 
malaria, tuberculosis (TB) and HIV, there is growing appreciation 
that many medicines will be used during pregnancy, intentionally 
or unintentionally – in the absence of robust safety data. The safety 
concerns are relevant to the pregnant woman and the fetus and 
have been highlighted in debates to determine first-line treatment 
for HIV-infected pregnant women.[1] Given the ethical challenges of 
enrolling pregnant women in clinical trials, the only feasible approach 
to assessing the safety of medicines is through pregnancy exposure 
registries (PERs) and by means of other observational studies.[2,3] 
Medication use during pregnancy is widespread and frequent in 
the developed world, but little is known of prevalence and patterns in 
African settings.[4,5] The gestational timing of the exposure, as well as 
dose and duration of exposure (i.e. intensity), are important factors 
when assessing potential effects on the fetus.[2] However, records are 
often absent, unclear or inaccurate in clinical case notes, particularly 
when resources are limited.[6] In African settings, where there is 
a high disease burden (infectious and non-infectious), there is a 
need to improve the science of documenting and analysing accurate 
information regarding medicine exposures in women immediately 
before and during pregnancy to assess the extent of use and safety.[7] 
As part of baseline investigations before piloting a provincial PER/
birth defect surveillance system (BDS), we aimed to determine the 
correlation between evidence of medicine exposure in pregnant 
women using provincial medicine and pharmacy digital recording 
platforms, and the medical records of prescribed and dispensed 
pharmacotherapy as completed by clinicians (clinical notes/
prescription charts). Our objective was to assess the validity of 
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Background. In African settings, where there is a high disease burden, there is a need to improve the science of documenting and analysing 
accurate information regarding medicine exposures in women immediately before and during pregnancy to assess the extent of use and 
safety in pregnant women and their unborn children. 
Objectives. To compare evidence of medicine use during pregnancy, as documented in paper-based clinical records (maternity case records 
(MCRs)) against electronic health information resources (Provincial Health Data Centre (PHDC)) and assess the level of concordance 
between the two as part of baseline investigations before piloting a provincial pregnancy exposure registry and birth defect surveillance 
system. The PHDC consolidates electronic clinical and pharmacy data. 
Methods. A folder review of completed pregnancies between November 2013 and January 2016 was conducted on randomly selected MCRs 
from midwife-run obstetric units and a secondary maternity hospital in Cape Town, South Africa. Medication exposures in the MCR were 
captured and compared with a customised PHDC data extract. The type and timing of drug exposures were compared. Total exposures 
were compiled from all data sources. 
Results. Two hundred and six MCRs from three facilities were sampled: 83 women had documented antiretroviral therapy (ART) exposure; 
all but 1 (1%) had been recorded in the PHDC extract. There was no evidence of ART use in the MCRs of 4 (5%) cases, despite evidence 
in the PHDC. There were imprecise drug names in the MCRs of 14 (17%) ART patients, discordant dates of onset between the MCRs and 
PHDC extracts in 10/83 (12%) and inaccurate medicine names and incorrect dates in 1 (1%) case each. Nine of 10 (90%) women who were 
administered antituberculosis medication were recorded in the PHDC extract. Ten of 21 (48%) isoniazid preventive therapy treatments 
appeared in the MCRs and PHDC; 9 (42%) in the PHDC only and 2 (10%) in the MCRs only. Half (n=18/36) of all antibiotic use was 
reflected only in the MCRs, while 13/36 (36%) appeared only in the PHDC extract. In the former cases, antibiotics used for treatment of 
sexually transmitted infections and urinary tract infections were dispensed from ward stock and not captured electronically. Antibiotics 
reflected only in the PHDC were either dispensed at a referral facility or before the first recorded antenatal clinic visit. Folic acid and iron 
were mostly documented in the MCR only (n=79/99 (80%) and n=107/128 (84%), respectively). However, analgesics and antihistamines 
more often appeared in the PHDC extract only (n=11/16 (73%) and n=5/5 (100%), respectively). 
Conclusions. The PHDC extract provided a better and more complete reflection of chronic drug exposures compared with the MCRs, 
especially when women sought care at facilities other than the antenatal care unit where they first attended, or when exposures occurred before 
the initial antenatal visit. The exception was antibiotics dispensed from ward stock to treat sexually transmitted and urinary tract infections.
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electronic medical record systems as a reflection of maternal exposures 
during pregnancy, with an emphasis on antiretroviral therapy (ART).
Methods
Setting and population
The Klipfontein-Mitchell’s Plain (KMP) sub-district of the Western 
Cape Province, South Africa, was identified as the geographical area 
for the PER/BDS pilot study. Maternity facilities comprise three 
midwife-run obstetric units (MOUs) (Gugulethu, Mitchell’s Plain 
and Hanover Park); one district hospital (Mitchell’s Plain District 
Hospital); one secondary hospital (Mowbray Maternity Hospital 
(MMH)) and a tertiary referral centre (Groote Schuur Hospital 
(GSH)). We selected three maternity facilities within the KMP sub-
district: Gugulethu and Mitchell’s Plain MOUs, and MMH. All three 
facilities use the same electronic pharmacy management system that 
records medicines dispensed, including ART. 
In the Western Cape, all patients in the public sector are allocated 
a unique patient identifier (folder number), which facilitates record 
linkage between various patient registration systems, including 
deaths and disease registers, the electronic pharmacy management 
system and the National Health Laboratory Service (NHLS). 
Any measurement of medicine exposure during pregnancy needs 
to be validated before being used for analyses aimed at assessing the 
impact of medicine exposures on various health outcomes. 
Information sources
The maternity case record (MCR) is a patient-held clinical document 
handed to women at their first antenatal visit and includes all clinical 
notes and information for the duration of the pregnancy and delivery. 
After birth, it is retained at the site of delivery, regardless of where the 
woman received antenatal care. Medication history is recorded in an 
initial assessment section and new prescriptions are documented in 
the consultation notes. 
Electronic pregnancy and dispensing data were obtained from an 
emergent consolidated data environment, the Provincial Health Data 
Centre (PHDC), which incorporates data from the following elements:
• Disease information systems for HIV and TB, essentially electronic 
registers that capture treatment initiation and regimens, and from 
which data are cascaded up to the province and are available to 
the PHDC.[8] 
• Hospital and primary healthcare clerical systems used for patient 
registration and recording of admissions, outpatient visits and, 
in some instances, visits to primary care clinics. Patients have a 
unique folder number across all hospitals and clinics. Diagnostic 
and procedural codes are available from the hospital clerical system 
for hospital visits and admissions, with variable completeness and 
accuracy.[9]
• Birth registers maintained at hospital and primary care level.
• Laboratory data, which are often the first indication of pregnancy 
when screening tests, e.g. for rhesus antibodies, are performed.
• Electronic dispensing data from two sources: a centralised 
dispensing system used across all 52 hospitals and ~50 of the 
largest clinics in the province, and prepackaged dispensing for 
patients with chronic conditions from a warehouse pharmacy. 
Data from these sources were consolidated by the PHDC, 
predominantly using the unique patient identifier to locate preg-
nancies and exposures in the sample. 
Study design
This was a validation study comparing information abstracted from a 
retrospective folder review with electronic data for the same variables 
in the same patients. We compared the medicine exposures recorded 
in randomly selected MCRs with a PHDC extract generated for these 
cases. 
Postnatal MCRs were randomly selected from the abovementioned 
three facilities and reviewed for medicine exposures. Data were 
recorded on an Excel spreadsheet by a single investigator (UM). 
Randomly selected folders of completed pregnancies that resulted 
in live births between 1 November 2013 and 31 January 2016 were 
retrieved from the medical records department of the three facilities 
and reviewed for analysis. The folder number and date of birth 
were included to enable linkage with electronic data. HIV and TB 
status and all medicine exposures, including supplements, with 
documented start dates, were also recorded.
Once the MCRs were selected, a staff member at the PHDC 
conducted a search of the provincial databases to extract the 
relevant patient data. The PHDC linked the electronic data with 
the MCR identifiers, allowing comparison of the two data sources. 
To ensure confidentiality, patient identifiers were scrambled and a 
code facilitating the matching with the cases was securely sent to the 
primary researcher (UM). 
Identifying pregnancies using the electronic health 
information system
A predefined search strategy was developed by the PHDC to identify 
women who sought care for a pregnancy-related condition. This 
approach involved the use of a series of electronic evidences (e.g. 
rhesus-antibody testing, International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10) diagnosis 
codes, International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) procedure codes, inpatient and outpatient 
obstetrics ward visits, and registration in a labour/delivery ward), 
which were pooled into a single pregnancy record. 
The pregnancy exposure period for each case was estimated using 
pregnancy-related evidence from electronic resources, assumptions 
regarding the gestational age at which most women first seek 
antenatal care, and a crude estimate of the average gestational age 
of live-born infants at birth. Assuming that the average gestational 
age at birth is ~40 weeks (~280 days from the first day of a woman’s 
last menstrual period), a period of 300 days prior to the date of the 
infant’s birth was used to capture data of all possible pregnancy 
exposures from dispensing data. Each was classified as a pregnancy 
exposure if the period of use (start and end dates) overlapped at any 
time with the pregnancy exposure period defined above. 
The type and timing of drug exposures recorded in the PHDC 
extract were compared with those in the MCRs. A difference of 
treatment initiation of <7 days between the two was regarded as 
consistent. The total number of exposures were compiled based on 
data derived from all data sources. 
Medicine exposures were categorised into the following: 
• ART
• anti-TB combination treatments 




• supplements, including folate, iron and vitamins B and C. 
Outcomes were categorised as the proportion of records as follows:
• There was complete concordance between the MCR and electronic 
system (medicine name and date of treatment initiation) (both).
• Medicine exposure was only recorded in the MCR and not reflected 
in the electronic record (MCR only).
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• Medicine exposure was only recorded in the electronic record and 
not in the MCR (PHDC only).
• Medicine exposure was recorded in the MCR and electronic 
record, but with inaccuracies or incomplete information in the 
MCR (both; MCR inaccurate).
• Medicine exposure was recorded in the MCR and electronic 
record, but the dates of treatment onset were discordant (both; 
dates discordant). 
• Medicine exposure was recorded in the MCR and electronic 
record, but with inaccuracies in medicine names in the MCR and 
discordance in dates of treatment initiation (both; MCR inaccurate 
and dates discordant). 
Descriptive statistics were used to report proportions and percentages 
of the various outcomes measured. 
Ethical approval
Ethical approval was obtained from the University of Cape Town’s 
Human Research Ethics Committee (ref. no. 541/2015). 
Results
MCRs (N=206) from the three facilities were reviewed (Table 1). Eighty-
five (41.3%) and 65 (31.6%) were sampled from Gugulethu and Mitchell’s 
Plain MOUs, respectively, and a further 56 (27.1%) from MMH. 
The median age of the women at delivery was 28.5 (interquartile 
range (IQR) 24.8 - 33.4) years and 84 (40.8%) were HIV-infected. All 
but 1 of the HIV-infected women received ART during pregnancy. 
The untreated woman had not attended antenatal services and first 
presented for care at the time of delivery. 
The comparisons between the MCR and PHDC extract for chronic 
(i.e. ART, TB treatment and antihypertensives) and episodic medi-
cations and supplements (antibiotics, antihistamine, influenza 
vaccine, vitamins and iron) are shown in Tables 2 and 3. There was 
no record of medicine use in either the PHDC extract or the MCRs 
in 25/206 (12.1%) of cases. 
Of the 83 women receiving ART during pregnancy, there were 
PHDC treatment records for all but 1 (1%). There was no record of 
ART in the MCRs for 4 (5%) women, despite electronic evidence 
of ART being dispensed. Imprecise drug names in the MCRs were 
noted in 14/83 (17%) of cases, discordant dates of medicine initiation 
between the data sources occurred in 10 (12%) cases and of both 
inaccurate medicine names and incorrect dates in 1 (1%) patient.
Based on the MCR review, 10 women were treated for TB during 
the antenatal period. All but 1 (90%) were reflected in the PHDC 
output. The single patient received a second-line regimen, including 
streptomycin, pyrazinamide, ethionamide and moxifloxacin. In one 
instance, there was PHDC evidence of initiation of TB treatment 
5 days before delivery, but no record of the TB episode in the MCR. 
In the electronic data systems, there was discordance between the 
data derived from the electronic TB register and those recorded in 
the pharmacy system, with only 3 of the 9 cases in the TB register 
reflecting anti-TB regimens in the pharmacy database. The electronic 
TB register does not provide names of the anti-TB drugs, but records 
the regimen (e.g. regimen 1). The date of switching from the initiation 
to maintenance phase of therapy is also not consistently provided. 
Ten of the 21 (48%) IPT cases were recorded accurately in both the 
MCR and PHDC. Of the remaining 11 cases, 9 (42%) were recorded 
in the PHDC only and 2 (10%) in the MCR only. Antihypertensive 
use was noted in 2 cases, both of which were recorded in the PHDC 
but only 1 in the MCR. In the latter case, there was also disparity 
in the reported date of treatment initiation between the two data 
sources. 
In cases of episodic treatment, drug exposures are usually recorded 
exclusively in the MCR or PHDC (Table 3). Influenza vaccine was 
administered as part of a clinical trial and therefore not recorded 
in the PHDC. One-half (n=18/36) of the instances of antibiotic use 
were reflected only in the MCR, while 13/36 (36%) appeared only in 
the PHDC extract. In the latter situations, the antibiotic had been 
dispensed either at a referral facility or on a date preceding the first 
recorded antenatal visit. 
Routine pregnancy supplements, such as folic acid and iron, were 
most often recorded in the MCR only (n=79/99 (80%) and n=107/128 
(84%), respectively). However, analgesics and antihistamines more 
often appeared in the PHDC extract only (n=11/16 (73%) and n=5/5 
(100%), respectively). 
Table 1. Maternal demographics  
Maternity records reviewed, N 206
Live births, n (%) 206 (100)
Maternal age at delivery, median (IQR) (years) 28.5 (24.8 - 33.4)
HIV-infected women, n (%) 84 (40.8)
HIV-infected women on ART during 
pregnancy, n (%)
83 (40.3)
Place of delivery of cases, n (%)  
Gugulethu MOU, n (%) 85 (41.3)
Mitchell’s Plain MOU, n (%) 65 (31.6)
Mowbray Maternity Hospital, n (%) 56 (27.2)
Women with no record of medicines used 
during pregnancy, n (%)
25 (12.1)
ART = antiretroviral therapy; MOU = midwife-run obstetric unit; IQR = interquartile 
range. 
Table 2. Recording of chronic treatments in the MCR v. PHDC
ARVs Anti-TB IPT Anti-HTNs 
Recorded correctly in MCR and PHDC, n (%) 53 (64) 4 (40) 10 (48) 0 (0)
Recorded only in PHDC, not in MCR, n (%) 4 (5) 1 (10) 7 (33) 1 (50)
Recorded only in MCR, n (%) 1 (1) 1 (10) 2 (10) 0 (0)
Recorded in MCR and PHDC, but inaccuracies or incomplete 
information in MCR, n (%)  
14 (17) 1 (10) 0 (0) 0 (0)
Recorded in MCR and PHDC, but discordance in dates of onset, n (%)  10 (12) 1 (10) 2 (10) 1 (50)
Recorded in MCR and PHDC, but inaccuracies in medicine names in 
MCR and discordance in dates of treatment onset between MCR and 
PHDC, n (%)
1 (1) 2 (20) 0 (0) 0 (0)
Women (total) with recorded exposures to specific medicine/s, N 83 10 21 2
MCR = maternity case record; PHDC = Provincial Health Data Centre; anti-TB = antituberculosis agents (e.g. pyrazinamide, isoniazid, ethambutol, rifampicin, streptomycin); 
ARVs = antiretrovirals; IPT = isoniazid preventive therapy; anti-HTNs = antihypertensives (e.g. methyldopa, enalapril, hydrochlorothiazide, nifedipine).
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Discussion
This analysis demonstrated that the PHDC extract was more reliable 
than the MCR in accurately recording ART and other chronic drug 
exposures. In all but 1 case, ART was recorded in the electronic 
records. In that instance, ART had been prescribed but was either 
not dispensed or the dispensing record could not be linked to the 
pregnancy. While the electronic TB register provided reasonably 
robust data on anti-TB treatment, only a small number of cases 
were recorded in pharmacy databases, as TB medication is usually 
dispensed directly to patients from open ward stock in the clinic 
rather than by pharmacies. There were no instances where TB 
medication was reflected in dispensing data but not in the TB register. 
Medicines that are frequently prescribed as part of routine care are 
often distributed in bulk to a clinic or ward to minimise pharmacy 
queues and reduce waiting times. These are then directly dispensed 
by the clinician. There is no patient-linked electronic register of ward 
stock items. At antenatal clinics, routine supplements, such as iron 
and folate, are dispensed from the ward stock without a clinic register 
to record the dates and duration of treatment. Antibiotics prescribed 
for sexually transmitted and urinary tract infections are similarly 
dispensed from ward stock in the MOUs and are not routinely 
captured on pharmacy systems. Therefore, compared with ART, there 
was less concordance in the recording of short-course treatments and 
routine pregnancy supplements. 
The influenza vaccine administered was part of a clinical trial 
and therefore did not appear on the electronic dispensing system. 
Many other short-course treatments were exclusively captured 
electronically and not found in MCRs. These included medicines 
prescribed to women before their first antenatal visit or at referral 
facilities other than where a woman booked for antenatal care. At 
hospitals, medicines prescribed and administered are recorded 
in a prescription chart that is kept in the hospital folder and 
not necessarily duplicated in the MCR. The PHDC extract was 
therefore able to provide information on early pregnancy exposures 
and medicines obtained from other health facilities. The value of 
electronic dispensing data as part of a longitudinal clinical record 
could be further improved if prescription charts were completed and 
sent to the pharmacy for capturing, even in cases where medicines 
are dispensed directly to patients from ward stock. There would be 
additional stock management benefits to this process.
The availability of computerised information regarding medicine use 
has provided tremendous opportunities internationally to assess the 
safety of medicines used by the general population. Data are collected 
prospectively, limiting recall bias and allowing for such information 
to be assessed in relation to specific medical events and outcomes at 
a later stage. 
The contribution of dose, duration and timing of exposure is 
particularly important in assessing the safety of medicines during 
pregnancy, given progressive fetal development and the fetus’s 
changing vulnerability to potentially toxic exposures.[10] Unlike the 
MCR, where usually only the medicine name and date of prescribing 
were documented, the PHDC extract could provide duration and 
dose of exposure and median time between prescription refills – a 
proxy indicator of patient adherence. In the case of prevention of 
mother-to-child transmission of HIV, where birth outcomes such 
as preterm delivery, intrauterine growth retardation, stillbirth and 
neonatal death are relevant, questions around the importance of 
extent of exposure have been raised.[11,12]
An important finding was the poor performance of the MCR 
as a reliable source for capturing medicines administered during 
pregnancy. This raises a number of systems issues that could be 
strengthened. Firstly, in the preprinted national MCR stationery 
record, there is no explicitly allocated section that prompts clinical 
staff to record drug exposures. Three short lines are provided for 
recording the patient’s medication history at the first antenatal 
visit. This section can only be completed if a highly abbreviated 
record of medicine exposures is given, e.g. ‘on ARVs’, in women 
initiated on ART before the first antenatal visit. We believe that the 
practice of accurate recording of medication use before and during 
pregnancy could be significantly strengthened by affording this 
critical component of the clinical encounter due importance in the 
medical record. 
Secondly, ongoing training regarding the importance of 
comprehensive drug history-taking and accurate and complete 
recording of medicine exposures during pregnancy as an essential 
component of the antenatal visit need to be incorporated into the 
national training curriculum for doctors and nurses. Not only is this 
important for medicolegal purposes, but also for clinically assessing 
whether the woman is being adequately and appropriately managed, 
whether the treatment is safe for the fetus, and to assess whether 
Table 3. Recording of episodic treatments in the MCR v. PHDC
  Folic acid Iron 
Influenza 
vaccine Analgesics Antibiotics 
Vitamins 
B and C Antihistamines 
Recorded correctly in MCR and PHDC, n (%) 13 (13) 10 (8) 0 (0) 1 (7) 3 (8) 8 (20) 0 (0)
Recorded only in PHDC, not in MCR, n (%) 7 (7) 8 (6) 0 (0) 11 (73) 13 (36)* 19 (46) 5 (100)
Recorded only in MCR, n (%) 79 (80) 107 (84) 33 (100) 3 (20) 18 (50) 14 (34) 0 (0)
Recorded in MCR and PHDC, but 
inaccuracies or incomplete information in 
MCR, n (%)
0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0)
Recorded in MCR and PHDC, but 
discordance in dates of onset, n (%)  
0 (0) 3 (2) 0 (0) 1 (7) 1 (3) 0 (0) 0 (0)
Recorded in MCR and PHDC, but 
inaccuracies in medicine names in MCR 
and discordance in dates of treatment onset 
between MCR and PHDC, n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Women (total) with recorded exposures to 
specific medicine/s, N
99 128 33 16 36 41 5
MCR = maternity case record; PHDC = Provincial Health Data Centre.
*In 4 women, antibiotic exposures were not recorded in the MCR, but found in the electronic medical record on more than one occasion. 
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any change in the woman’s health could be attributed to an adverse 
drug reaction. Recent studies on ART safety have highlighted the 
importance of early recognition of adverse drug reactions in pregnant 
women (including attributing suspicion to current medication) to 
avoid the potentially fatal consequences of these effects.[1,13] 
Study limitations
The objective of this article was not to provide an indication of 
the nature and frequency of drug use in pregnant women in our 
setting, as the sample was purposively selected to assess the accuracy 
and concordance in recording of the different types of exposures, 
particularly focusing on ART.
While this analysis cannot rule out the possibility of false positives 
in the MCR, it is unlikely to be the case, as clinicians are more likely 
to under-report drug exposures than report false exposures. There is 
often significant under-reporting of over-the-counter medication and 
herbal/traditional medicines,[14] as well as medicines acquired outside 
of the provincial pharmacy system, which are not recorded in either 
the electronic health records or the MCRs.
The evidence obtained from the MCRs and PHDC extract describes 
self-reported medicine use and dispensed therapeutic drugs. There 
can be no guarantee that the drugs were taken as prescribed; as with 
all dispensing data, exposures may be overestimated.[15]
We conservatively assessed pregnancy exposures as those that 
occurred up to 300 days before the infant’s date of birth. While this may 
have led to overestimation, it afforded us the opportunity to assess which 
medicines were taken during the critical period around conception and 
implantation. With this approach we could identify exposures during the 
early pregnancy period before the first antenatal visit. 
We did not apply a longitudinal approach to assessing data on 
exposure, focusing only on the date of onset of treatment. While 
duration of treatment or end dates are recorded in the electronic 
health records, these are not often documented in MCRs. 
Conclusions
The existing electronic pharmacy and patient management systems 
provide a better and more complete reflection of chronic drug 
exposures than the paper-based MCR, particularly when women 
seek care at clinics or facilities other than the antenatal care unit 
where they initially booked. These include exposures that occurred 
prior to the initial antenatal booking visit. However, the quality of 
drug exposure information captured in MCRs by clinicians (type 
of medicine, indication and dates of use) during pregnancy needs 
to be improved by training and mentoring of antenatal staff on the 
correct recording of drug exposures. Medicines dispensed to patients 
from ward stock (e.g. routine supplements, antibiotics and vaccines) 
cannot be verified by the electronic data management system. Until 
all medicine use at all facilities is routinely captured onto pharmacy 
and other electronic databases housed by the province, the MCR 
should be used as a secondary data source for assessing medicine 
exposures during pregnancy and any potential impact these may have 
on the mother or fetus. 
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